Shopping Cart 0
Cart Subtotal
USD 0

Agenus Inc (AGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Agenus Inc (Agenus) is a clinical-stage immuno-oncology company that discovers, develops and commercializes a wide range of immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company's pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company's technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. The company has collaboration with several pharmaceutical companies such as GSK, Incyte, and Merck; and universities such as UC San Francisco and UW Seattle. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.

Agenus Inc (AGEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Agenus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11

Agenus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Agenus Inc, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Agenus Acquires Antibody Manufacturing Facilities from XOMA 14

Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 16

Agenus Acquires Antibody Assets of Celexion 17

Venture Financing 18

PhosImmune Raises Funds through Venture Financing 18

Partnerships 19

Agenus Enters into Agreement with National Cancer Institute 19

4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 20

Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 21

Licensing Agreements 22

Agenus Enters into Licensing Agreement with IONTAS 22

Agenus Enters into Licensing Agreement with Diatheva 23

Merck Extends Licensing Agreement with Agenus 24

Incyte Amends Licensing Agreement with Agenus 25

Agenus Enters into Licensing Agreement with Ludwig Institute 27

Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 28

Agenus Enters Into Licensing Agreement With VaxLogic For QS-21 Stimulon 29

PhosImmune Enters into Licensing Agreement with Pure MHC 30

Equity Offering 31

Agenus to Raise Funds through Public Offering of Shares 31

Agenus Plans to Raise Funds through Public Offering of Shares 32

Celexion Sells its Stock to Agenus for USD4.3 Million 33

Agenus Plans to Raise Funds through Public Offering of Shares 34

Agenus Raises USD80 Million in Public Offering of Shares 35

Agenus Raises USD35 Million in Private Placement of Common Stock 37

Agenus Completes Public Offering Of Shares For USD 60 Million 39

Agenus Completes Private Placement Of Shares For USD 10 Million 41

Agenus Completes Private Placement Of Shares For USD 8 Million 42

Agenus Completes Private Placement Of Shares For USD 3 Million 43

Debt Offering 44

Agenus Raises USD100 Million in Private Placement of 13.5% Notes 44

Agenus Completes Private Placement Of Notes Due 2015 For USD 5 Million 46

Asset Transactions 47

XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 47

Agenus Enters into Royalty Monetization Agreement with HealthCare Royalty Partners 48

Acquisition 50

Agenus Acquires PhosImmune 50

Agenus Completes Acquisition Of 4-Antibody For USD 50 Million 51

Agenus Inc-Key Competitors 53

Agenus Inc-Key Employees 54

Agenus Inc-Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Recent Developments 56

Strategy And Business Planning 56

Oct 23, 2017: Agenus creates New Cell Therapy subsidiary named AgenTus Therapeutics 56

Financial Announcements 57

Aug 09, 2018: Agenus reports second quarter 2018 financial results and provides corporate update 57

May 07, 2018: Agenus Annnounces First Quarter 2018 Financial Results 58

Nov 07, 2017: Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update 59

Aug 03, 2017: Agenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update 60

May 04, 2017: Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update 61

Mar 09, 2017: Agenus Reports Fourth Quarter and Full Year 2016 Results 63

Corporate Communications 65

Oct 23, 2017: Bruno Lucidi Appointed Chief Executive Officer of AgenTus Therapeutics, The Cell Therapy Subsidiary of Agenus 65

Mar 30, 2017: Agenus Restructures Business to Sharpen Focus on Clinical Development of Cancer Therapies 66

Jan 30, 2017: Agenus Appoints Jean-Marie Cuillerot, M.D. Chief Medical Officer 67

Product News 68

05/17/2018: Agenus to Present Clinical Data on AGEN2034 at ASCO 2018 68

Jan 22, 2018: Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034) 69

Clinical Trials 70

Jun 04, 2018: Agenus Presents Clinical Response of AGEN2034 (anti-PD-1) at ASCO 2018 70

Jun 04, 2018: Agenus Presents Clinical Responses of AGEN1884 at ASCO 2018 71

May 17, 2018: Agenus to Present Clinical Data on AGEN-1884 at ASCO 2018 72

Apr 11, 2018: Agenus Abstracts Accepted for Presentation at the AACR 2018 Annual Meeting 73

Nov 09, 2017: Agenus To Present Data on AGEN2034 (PD-1) at SITC 2017 74

Nov 09, 2017: Agenus To Present on Lead Antibody Program AGEN1884 (CTLA-4) at SITC 2017 75

Jun 05, 2017: Agenus anti-CTLA-4 antibody shows strong safety and tolerability 76

May 22, 2017: Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting 77

Apr 05, 2017: Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax 78

Mar 07, 2017: Agenus Abstract Accepted for Presentation at the American Association for Cancer Research (AACR) 2017 Annual Meeting 79

Appendix 80

Methodology 80

About GlobalData 80

Contact Us 80

Disclaimer 80


List Of Figure

List of Figures

Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Agenus Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Agenus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Agenus Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11

Agenus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Agenus Acquires Antibody Manufacturing Facilities from XOMA 14

Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 16

Agenus Acquires Antibody Assets of Celexion 17

PhosImmune Raises Funds through Venture Financing 18

Agenus Enters into Agreement with National Cancer Institute 19

4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 20

Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 21

Agenus Enters into Licensing Agreement with IONTAS 22

Agenus Enters into Licensing Agreement with Diatheva 23

Merck Extends Licensing Agreement with Agenus 24

Incyte Amends Licensing Agreement with Agenus 25

Agenus Enters into Licensing Agreement with Ludwig Institute 27

Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 28

Agenus Enters Into Licensing Agreement With VaxLogic For QS-21 Stimulon 29

PhosImmune Enters into Licensing Agreement with Pure MHC 30

Agenus to Raise Funds through Public Offering of Shares 31

Agenus Plans to Raise Funds through Public Offering of Shares 32

Celexion Sells its Stock to Agenus for USD4.3 Million 33

Agenus Plans to Raise Funds through Public Offering of Shares 34

Agenus Raises USD80 Million in Public Offering of Shares 35

Agenus Raises USD35 Million in Private Placement of Common Stock 37

Agenus Completes Public Offering Of Shares For USD 60 Million 39

Agenus Completes Private Placement Of Shares For USD 10 Million 41

Agenus Completes Private Placement Of Shares For USD 8 Million 42

Agenus Completes Private Placement Of Shares For USD 3 Million 43

Agenus Raises USD100 Million in Private Placement of 13.5% Notes 44

Agenus Completes Private Placement Of Notes Due 2015 For USD 5 Million 46

XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 47

Agenus Enters into Royalty Monetization Agreement with HealthCare Royalty Partners 48

Agenus Acquires PhosImmune 50

Agenus Completes Acquisition Of 4-Antibody For USD 50 Million 51

Agenus Inc, Key Competitors 53

Agenus Inc, Key Employees 54

Agenus Inc, Subsidiaries 55

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Agenus Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Agenus Inc (Agenus) is a clinical-stage immuno-oncology company that discovers, develops and commercializes a wide range of immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company's pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company's technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. The company has collaboration with several pharmaceutical companies such as GSK, Incyte, and Merck; and universities such as UC San Francisco and UW Seattle. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.

Agenus Inc (AGEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Agenus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11

Agenus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Agenus Inc, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Agenus Acquires Antibody Manufacturing Facilities from XOMA 14

Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 16

Agenus Acquires Antibody Assets of Celexion 17

Venture Financing 18

PhosImmune Raises Funds through Venture Financing 18

Partnerships 19

Agenus Enters into Agreement with National Cancer Institute 19

4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 20

Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 21

Licensing Agreements 22

Agenus Enters into Licensing Agreement with IONTAS 22

Agenus Enters into Licensing Agreement with Diatheva 23

Merck Extends Licensing Agreement with Agenus 24

Incyte Amends Licensing Agreement with Agenus 25

Agenus Enters into Licensing Agreement with Ludwig Institute 27

Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 28

Agenus Enters Into Licensing Agreement With VaxLogic For QS-21 Stimulon 29

PhosImmune Enters into Licensing Agreement with Pure MHC 30

Equity Offering 31

Agenus to Raise Funds through Public Offering of Shares 31

Agenus Plans to Raise Funds through Public Offering of Shares 32

Celexion Sells its Stock to Agenus for USD4.3 Million 33

Agenus Plans to Raise Funds through Public Offering of Shares 34

Agenus Raises USD80 Million in Public Offering of Shares 35

Agenus Raises USD35 Million in Private Placement of Common Stock 37

Agenus Completes Public Offering Of Shares For USD 60 Million 39

Agenus Completes Private Placement Of Shares For USD 10 Million 41

Agenus Completes Private Placement Of Shares For USD 8 Million 42

Agenus Completes Private Placement Of Shares For USD 3 Million 43

Debt Offering 44

Agenus Raises USD100 Million in Private Placement of 13.5% Notes 44

Agenus Completes Private Placement Of Notes Due 2015 For USD 5 Million 46

Asset Transactions 47

XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 47

Agenus Enters into Royalty Monetization Agreement with HealthCare Royalty Partners 48

Acquisition 50

Agenus Acquires PhosImmune 50

Agenus Completes Acquisition Of 4-Antibody For USD 50 Million 51

Agenus Inc-Key Competitors 53

Agenus Inc-Key Employees 54

Agenus Inc-Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Recent Developments 56

Strategy And Business Planning 56

Oct 23, 2017: Agenus creates New Cell Therapy subsidiary named AgenTus Therapeutics 56

Financial Announcements 57

Aug 09, 2018: Agenus reports second quarter 2018 financial results and provides corporate update 57

May 07, 2018: Agenus Annnounces First Quarter 2018 Financial Results 58

Nov 07, 2017: Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update 59

Aug 03, 2017: Agenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update 60

May 04, 2017: Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update 61

Mar 09, 2017: Agenus Reports Fourth Quarter and Full Year 2016 Results 63

Corporate Communications 65

Oct 23, 2017: Bruno Lucidi Appointed Chief Executive Officer of AgenTus Therapeutics, The Cell Therapy Subsidiary of Agenus 65

Mar 30, 2017: Agenus Restructures Business to Sharpen Focus on Clinical Development of Cancer Therapies 66

Jan 30, 2017: Agenus Appoints Jean-Marie Cuillerot, M.D. Chief Medical Officer 67

Product News 68

05/17/2018: Agenus to Present Clinical Data on AGEN2034 at ASCO 2018 68

Jan 22, 2018: Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034) 69

Clinical Trials 70

Jun 04, 2018: Agenus Presents Clinical Response of AGEN2034 (anti-PD-1) at ASCO 2018 70

Jun 04, 2018: Agenus Presents Clinical Responses of AGEN1884 at ASCO 2018 71

May 17, 2018: Agenus to Present Clinical Data on AGEN-1884 at ASCO 2018 72

Apr 11, 2018: Agenus Abstracts Accepted for Presentation at the AACR 2018 Annual Meeting 73

Nov 09, 2017: Agenus To Present Data on AGEN2034 (PD-1) at SITC 2017 74

Nov 09, 2017: Agenus To Present on Lead Antibody Program AGEN1884 (CTLA-4) at SITC 2017 75

Jun 05, 2017: Agenus anti-CTLA-4 antibody shows strong safety and tolerability 76

May 22, 2017: Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting 77

Apr 05, 2017: Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax 78

Mar 07, 2017: Agenus Abstract Accepted for Presentation at the American Association for Cancer Research (AACR) 2017 Annual Meeting 79

Appendix 80

Methodology 80

About GlobalData 80

Contact Us 80

Disclaimer 80


List Of Figure

List of Figures

Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Agenus Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Agenus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Agenus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Agenus Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Agenus Inc, Medical Devices Deals, 2012 to YTD 2018 11

Agenus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Agenus Acquires Antibody Manufacturing Facilities from XOMA 14

Agenus Enters Acquires Rights to Cell Line Development Technology from Selexis 16

Agenus Acquires Antibody Assets of Celexion 17

PhosImmune Raises Funds through Venture Financing 18

Agenus Enters into Agreement with National Cancer Institute 19

4-Antibody And Ludwig Institute Enter Into Agreement With Recepta Biopharma For Oncology Research 20

Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 21

Agenus Enters into Licensing Agreement with IONTAS 22

Agenus Enters into Licensing Agreement with Diatheva 23

Merck Extends Licensing Agreement with Agenus 24

Incyte Amends Licensing Agreement with Agenus 25

Agenus Enters into Licensing Agreement with Ludwig Institute 27

Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 28

Agenus Enters Into Licensing Agreement With VaxLogic For QS-21 Stimulon 29

PhosImmune Enters into Licensing Agreement with Pure MHC 30

Agenus to Raise Funds through Public Offering of Shares 31

Agenus Plans to Raise Funds through Public Offering of Shares 32

Celexion Sells its Stock to Agenus for USD4.3 Million 33

Agenus Plans to Raise Funds through Public Offering of Shares 34

Agenus Raises USD80 Million in Public Offering of Shares 35

Agenus Raises USD35 Million in Private Placement of Common Stock 37

Agenus Completes Public Offering Of Shares For USD 60 Million 39

Agenus Completes Private Placement Of Shares For USD 10 Million 41

Agenus Completes Private Placement Of Shares For USD 8 Million 42

Agenus Completes Private Placement Of Shares For USD 3 Million 43

Agenus Raises USD100 Million in Private Placement of 13.5% Notes 44

Agenus Completes Private Placement Of Notes Due 2015 For USD 5 Million 46

XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 47

Agenus Enters into Royalty Monetization Agreement with HealthCare Royalty Partners 48

Agenus Acquires PhosImmune 50

Agenus Completes Acquisition Of 4-Antibody For USD 50 Million 51

Agenus Inc, Key Competitors 53

Agenus Inc, Key Employees 54

Agenus Inc, Subsidiaries 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Agenus Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.